Sylentis Presenta Resultados clínicos del SYL1001 ( Tivanisiran ) .

Picar en el texto :

Polypeptides as Anticancer Agents.

Recent Progress of Marine Polypeptides as Anticancer.

Agents Marine Polypeptides as Anticancer Agents.

期刊年卷：Recent Pat Anticancer Drug Discov 2018 Apr 29

作者列表：Zheng L, Lin X, Yuan Z, Liu M, Cao S, Zhang F, Linhardt RJ

BACKGROUND: Marine environment constitutes an almost infinite resource for novel anticancer drugs discovery. The biodiversity of marine organisms provides a rich source for the discovery and development of novel anticancer peptides in the treatment of human cancer. Marine peptides represent a new opportunity to obtain lead compounds in biomedical field, particularly for cancer therapy.

OBJECTIVE: Providing an insight of the recent progress of patented marine peptides and presenting information about the structures and mechanistic mode of anticancer activities of these marine peptides.

METHOD: We reviewed recent progress on the patented anticancer peptides from marine organisms according to their targets on different signal pathways. This work focuses on relevant recent patents (2010-2018) that entail the anticancer activity with associated mechanism and related molecular diversity of marine peptides. The related cellular signaling pathways for novel peptides that induce apoptosis and affect tubulin-microtubule equilibrium, angiogenesis and kinase activity that are related to the anticancer and related pharmacological properties are also discussed.

RESULTS: The recent patents (2010-2018) of marine peptides with anticancer activity were reviewed, and the anticancer activity of marine peptides with associated mechanism and related molecular diversity of marine peptides were also discussed.

CONCLUSION:Marine peptides possess chemical diversity and displays potent anticancer activity via targeting different signal pathways. Some of the marine peptides are promising to be developed as novel anticancer agents.

UK . Error en detección de cáncer de mama podría haber acortado la vida de cientos de mujeres en el Reino Unido

Agencia AFP

Una "deficiencia grave" en el sistema de detección del cáncer de mama en Reino Unido podría haber "acortado la vida" de entre 135 y 270 mujeres,anunció el miércoles el ministro de Salud, Jeremy Hunt, ante el parlamento.

Según el ministro, el error concierne a un "algoritmo informático" y se remonta a 2009. Fue detectado a raíz de un análisis de datos realizado por el organismo de salud Public Health England (PHE).

"Según las últimas estimaciones que he recibido del PHE, se calcula que entre 2009 y 2018, 450.000 mujeres de entre 68 y 71 años no fueron invitadas a hacer su último control", declaró.

...